Guido G.
- Country
- Italy
- Department
- Hematology
Research Overview
- Phase II Study of Pirtobrutinib as Frontline Therapy in Elderly Unfit or Frail Patients with Mantle Cell Lymphoma
- Phase II Evaluation of Ibrutinib and Rituximab in Treatment-Naïve CD20-Positive Marginal Zone B-Cell Lymphoma Patients Requiring Systemic Therapy
- Phase 3 Randomized Open-Label Trial Comparing Brentuximab Vedotin Plus AVD Versus ABVD in Advanced Classical Hodgkin Lymphoma Patients
Data & Insights
Has run more than one trial at 93 of 197 partner sites.
Specializations
Large B-Cell Lymphoma Research
The investigator specializes in treating Diffuse Large B-Cell Lymphoma (DLBCL), with particular focus on elderly and high-risk patient populations. Their research encompasses novel therapeutic approaches including immunochemotherapy combinations and targeted treatments.
- Elderly patient treatment protocols
- ABC-DLBCL interventions
- Innovative drug combinations
Hodgkin Lymphoma Studies
Expertise in both early-stage and advanced Classical Hodgkin Lymphoma (cHL) treatment, with emphasis on radiation-free approaches and novel therapeutic combinations. The investigator focuses on metabolic tumor volume assessment and response-adapted therapy.
- Early-stage HL management
- Advanced disease protocols
- PET-guided treatment strategies
Indolent Lymphoma Management
Specialized research in Follicular Lymphoma and Marginal Zone Lymphoma, exploring various therapeutic combinations and treatment durations. The investigator's work includes both frontline therapy and management of relapsed/refractory disease.
- MALT lymphoma protocols
- Novel drug combinations
- Maintenance therapy approaches
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.